FDA Approves MORPHINE SULFATE — Amneal Pharmaceuticals of New York LLC
# FDA Approves Amneal Pharmaceuticals' Generic Morphine Sulfate Oral Formulation Amneal Pharmaceuticals of New York LLC received FDA approval for its generic morphine sulfate oral formulation (ANDA200411), expanding competitive options in the opioid market and likely pressuring prices for this widely-used pain management medication. The approval strengthens Amneal's portfolio in the generic pharmaceutical space and increases consumer access to more affordable morphine sulfate alternatives.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day